Demonstration Formulary
3 Respiratory system
03-14 Monoclonal Antibody
| Benralizumab Fasenra® |
|
Formulary
|
|
 NICE TA565: Benralizumab for treating severe eosinophilic asthma |
|
| Mepolizumab Nucala® |
|
Formulary
|
In line with NICE |
|
NICE TA671: Mepolizumab for treating severe eosinophilic asthma |
|
|
| Omalizumab Xolair® |
|
Formulary
|
For specialist use only in line with NICE guidance below NHS England is the responsible commissioner for use in Asthma
|
|
NICE TA278: Omalizumab for treating severe persistent allergic asthma NICE TA339: Omalizumab for previously treated chronic spontaneous urticaria |
|
|
| Reslizumab Cinqaero® |
|
Formulary
|
For specialist use only in line with NICE NHS England is the responsible commissioner for use in Asthma |
|
NICE TA479: Reslizumab for treating severe eosinophilic asthma |
|
|
Links
BCICB Asthma Treatment Guidelines - Adolescents 12-17 years old - BCICB Asthma Treatment Guidelines - Adults 18+
- BCICB Asthma Treatment Guidelines For Children Under 12
- BCICB COPD Inhaler Treatment Guidelines
- BCICB Difficult Asthma Referral Pathway - Adults 18+
- COVID-19: information for the respiratory community
- Greener Inhaler Guide Switching Information
- How to improve respiratory control in asthma and COPD
- NICE CG115: Chronic obstructive pulmonary disease in over 16s: diagnosis and management
- NICE TA10: Guidance on the use of inhaler systems (devices) in children under the age of 5 years with chronic asthma
- NICE TA138: Inhaled corticosteroids for the treatment of chronic asthma in adults and in children aged 12 years and over
- NICE TA278: Omalizumab for treating severe persistent allergic asthma
- NICE TA339: Omalizumab for previously treated chronic spontaneous urticaria
- NICE TA38: Inhaler devices for routine treatment of chronic asthma in older children (aged 5–15 years)
- NICE TA431: Mepolizumab for treating severe refractory eosinophilic asthma
- NICE TA479: Reslizumab for treating severe eosinophilic asthma
- NICE TA565: Benralizumab for treating severe eosinophilic asthma
- NICE TA671: Mepolizumab for treating severe eosinophilic asthma